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Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by synovial inﬂammation
and destruction of joints. Over 20 years ago, tumour necrosis factor alpha (TNFa) was identiﬁed as a
key player in a cytokine network, whose multifunctional effects could account for both the inﬂam-
mation and destruction in RA. The remarkable efﬁcacy of TNF inhibitors in the treatment of RA has
resulted in extensive research addressing the regulation of TNFa production responsible for this
excessive production.
The discovery of autoimmunity to citrullinated protein/peptide antigens (ACPA) has led the
concept that ACPA may be the essential link between disease susceptibility factors and the produc-
tion of TNFa, which ultimately accounts for the disease phenotype. In this review we will consider
(1) the mechanisms of citrullination, both physiological and pathological, (2) how known genetic
and environmental factors could drive this peculiar form of autoimmunity and (3) how the immune
response could lead to excessive production of TNFa by the synovial cells and ultimately to the
disease phenotype (Fig. 1).
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.
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Citrullination (also commonly referred to as deimination) is the
post-translational modiﬁcation of the positively charged amino
acid arginine, to a neutral citrulline. Citrullination in the context
of a peptide backbone is catalysed by peptidylarginine deiminase
(PAD) enzymes. The conversion of a positively charged peptidy-
larginine sidechain to a comparatively neutral peptidylcitrulline
can alter the three-dimensional structure of the protein and its sol-
ubility in water. This is important in generating structural proteins,
but in the context of RA, may lead to the breaching of immunolog-
ical tolerance as the neo-epitopes that could be generated may not
be expressed in the thymus or bone marrow during lymphocyte
selection.
Citrullination has numerous essential physiological roles in a
variety of cells and tissues in the body. Citrullination of structural
proteins such as pro-ﬁlaggrin and keratin in the skin facilitate pro-
teolysis and cross-linking of the proteins which contributes to cor-
niﬁcation [2,3]. In the nervous system, citrullination of myelin
basic protein (MBP) is essential for the electrical insulation offered
by myelin sheaths [3,4]. When trichohyalin, a structural proteincal Societies. Published by Elsevier
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nables).that bundles cytokeratin ﬁlaments, is citrullinated, it contributes
to the maturation of hair cuticle cells [2,5]. Citrullination also
controls the functions of histones as support structures and tran-
scriptional control elements for DNA [6,7]. Furthermore, hypercit-
rullination of histones is needed for formation of neutrophil
extracellular traps, part of the innate immune system response to
bacterial infection [8,9].
The activity of PAD enzymes is dependent on high concentra-
tions of calcium (Ca2+) [10]. As the Ca2+ concentrations required
for PAD activity are 100 fold higher than those present in intact
unstimulated cells, citrullination is likely to occur in conditions
which lead to mobilisation of free intracellular calcium, such as
chemokine receptor ligation, apoptosis, necrosis and cellular differ-
entiation [11]. The high calcium concentration needed in vitro also
suggests activating mechanisms that may modulate this require-
ment in vivo [12]. However peptidylarginine deiminases may
preferentially deiminate peptidylarginine bearing extracellular
substrates such as cytokines, collagen, ﬁbronectin and ﬁbrinogen
in the extracellular environment, where calcium concentrations
are more optimal for their activity.
Five PAD enzymes (PAD1–4 and PAD6) have been identiﬁed in
humans, which are all encoded by a single gene cluster on chromo-
some 1p35–36. PAD homologs for some or all of these enzymes
have also been found in other eukaryotes, with similar genomic
organisation across species [4,13]. However, a prokaryotic enzyme
with PAD activity has only been described in one bacterium toB.V. Open access under CC BY-NC-ND license.
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in periodontitis. This enzyme shows very limited sequence homol-
ogy with human PADs, but shares a common membership of the
guanidino-group modifying enzyme superfamily [16]. Unlike the
human PAD enzymes, P. gingivalis PAD (PPAD) is not Ca2+ depen-
dent, can convert free l-arginine [16] and only citrullinates car-
boxy-terminal arginines [14,15].
Human PAD enzymes show a characteristic tissue distribution.
PAD1 is predominantly expressed in the epidermis. PAD2 is the
most widely expressed, with the highest levels found in skeletal
muscle, secretory glands, brain and spleen. PAD3 is expressed in
hair follicles and the upper epidermal layer. PAD4 is expressed in
white blood cells and most well characterised in granulocytes.
PAD6 is only found in eggs, ovaries and in early embryos [4,17].
With the exception of PAD4, which has a nuclear localisation se-
quence, the intracellular presence of PAD enzymes is restricted to
the cytoplasm.
PAD2 and 4 are the family members that have been studied
most extensively in the context of RA. This is because their tissue
distribution would predict that both enzymes would be found
within the joint, which is enriched for myeloid cells. Indeed, both
PAD2 and PAD4, together with citrullinated proteins, have been
demonstrated in the synovial ﬂuid and the synovial membrane
[18,19]. Therefore, at present, PAD2 and PAD4 are the strongest
candidates for generating the citrullinated antigens that are tar-
geted in the rheumatoid joint. Several reports have demonstrated
that citrullinated proteins accumulate at sites of inﬂammation
[20–22]. Citrullinated ﬁbrin and vimentin have been observed in
the synovium (outlined in [23]). We demonstrated citrullinated
a-enolase detectable at similar levels in the synovial ﬂuid from
patients with RA and spondyloarthritis [19], but undetectable in
non-inﬂamed osteoarthritis samples. Importantly the autoanti-
body response to the citrullinated a-enolase was restricted to pa-
tients with RA.
2. Induction of the autoantibody response to citrullinated
proteins
The classical paradigm for induction of autoreactivity in any
autoimmune disease is the interaction of genetic susceptibility fac-
tors with environmental factors to produce a surprisingly limited
repertoire of disease-speciﬁc antibodies, which cause the associ-
ated pathology. In the case of RA, characterisation of the autoim-
mune response to speciﬁc citrullinated proteins has done much
to unravel this gene/environment/autoimmunity triad.
2.1. Autoantibodies to citrullinated proteins in RA
The presence of rheumatoid factor – RF (an antibody reactive
with the Fc portion of IgG) in RA individuals contributed towards
RA being termed an ‘autoimmune’ disease, and has been a compo-
nent of the classiﬁcation criteria for many years [24]. However, the
presence of RF is not speciﬁc for RA, but is thought to be the con-
sequence of immune activation [25,26]. The second-generation
cyclic citrullinated peptide (CCP) assays, now widely used in
diagnostic laboratories and included in the new 2010 ACR/EULAR
classiﬁcation criteria, evolved by selecting randomly generated
citrulline-containing peptides from a large panel which were
tested against RA and control serum, with the sequences giving
the best discrimination in diagnostic sensitivity and speciﬁcity
being adopted for clinical use. Anti-CCP antibodies have been
detected prior to the development of clinically apparent RA [27]
and are associated with more severe and erosive disease (reviewed
by Zendman et al. [28]). In spite of being a powerful diagnostic tool,
the cyclic citrullinated peptides used in the CCP assay are of limiteduse for understanding the disease aetiology and pathogenesis of RA
as they do not correspond to in vivo generated citrullinated pro-
teins. However, four citrullinated proteins that are targeted by
anti-citrullinated protein antibodies, and are present in the joint,
are now well established as autoantigens: citrullinated ﬁbrino-
gen/ﬁbrin [29], vimentin [18], collagen type II [30], and a-enolase
[31], with further proteins awaiting identiﬁcation and character-
isation (reviewed by Wegner et al. [15]).
2.2. Genetic factors contributing to the autoantibody response to
citrullinated proteins
Amongst the major and best-studied genetic risk factors identi-
ﬁed so far for the development of RA is a group of MHC class II al-
leles, namely HLA-DR4, -DR1 and -DR10, principally DRB1⁄0401,
⁄0404, ⁄0408, ⁄0405, ⁄0101, ⁄0102, ⁄1001 and ⁄1402 [32]. All share
variants of the Q/R-K/R-R-A-A amino acid motif, termed the ‘shared
epitope’ (SE), present in the third hypervariable region of the DRb1
chain and which constitutes part of the P4 pocket of the peptide
binding groove [33]. The SE has been shown by many to be associ-
ated with the ACPA positive subset of RA [34,35]. However, there is
much speculation in the literature regarding the underlying mech-
anism of the SE-RA association. Hypotheses include a direct role of
the SE on increased afﬁnity and presentation of autoantigens and
subsequent activation of self-reactive T cells [36], decreased acti-
vation of regulatory T cells [32], altered thymic T cell repertoire
selection [37], and the SE being an innate immune system activator
[38,39]. Another genetic risk factor for ACPA positive RA, but also
for other autoimmune diseases, is the susceptibility allele 620W
of PTPN22, a gene which encodes a tyrosine phosphatase involved
in T and B cell signaling [40,41]. A gene in the tumor necrosis factor
receptor-associated factor 1-C5 (TRAF1-C5) region has also been
shown to associate with ACPA-positive RA [42]. Polymorphisms
in the human PADI4 gene were ﬁrst associated with RA in a Japa-
nese cohort [43]. Patients with the susceptibility haplotype were
more likely to be anti-CCP antibody positive. The association with
RA has been conﬁrmed in a number of other Asian cohorts [44–46],
although independent of anti-CCP status in a large Korean cohort
[47]. Conﬂicting ﬁndings have been reported with Caucasian
cohorts [48–52] and a large case-control study of over 5500 UK
Caucasian patients showed no association [53]. The reasons for this
discrepancy are unclear.
2.3. Environmental factors contributing to the autoantibody response
to citrullinated proteins
Environmental factors are considered to contribute to the onset
of RA in a genetically predisposed individual. Evidence mainly
stems from the low disease concordance rate (15%) in monozygotic
twins [54] and the declining incidence of RA in genetically predis-
posed populations such as the Pima Indians [55,56]. Although a
number of environmental exposures have been linked to RA
including smoking, periodontitis, hormonal factors and exposure
to silica [57,58], smoking is the most clearly established [59–62].
2.3.1. Smoking
The link between RA and smoking was ﬁrst recognized in 1987
[63] as an unexpected ﬁnding in a study investigating the associa-
tion between RA and the use of oral contraceptives, and later con-
ﬁrmed in a number of case-control and cohort studies (reviewed
by Sugiyama et al. [64]). The most striking results were from the
Arthritis and Rheumatism Council Twin Study, where 13 pairs of
monozygotic twins, discordant for RA and smoking, were identi-
ﬁed, and in 12 out of 13 cases the RA patient was also the smoker
[60].
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provided by studies of gene-environment interactions. Klareskog
and colleagues were the ﬁrst to report that both smoking and the
SE were risk factors for anti-CCP antibody positive RA but not
anti-CCP negative and that the presence of both factors was asso-
ciated with a striking odds ratio for RA development [34]. They
proposed that smoking, in the presence of HLA-DR SE alleles, acti-
vates an antigen speciﬁc autoimmune response to citrullinated
proteins, which ultimately leads to the development of RA. We re-
cently observed that this gene-environment interaction was even
stronger for the subset of anti-CCP positive patients that also car-
ried antibodies to the immunodominant epitope of citrullinated
a-enolase (CEP-1) [65]. However others have reported similar ﬁnd-
ings with an overlapping subset deﬁned by antibodies to a citrulli-
nated vimentin peptide. It therefore seems likely that the smoking
and shared epitope interaction facilitates immunity to multiple dif-
ferent citrullinated epitopes and so broadens the immune response
in RA [66].
Exactly how smoking contributes to RA, and why smoking is
linked to the development of ACPA positive RA in a particular ge-
netic background, is the subject of ongoing investigations (Fig. 1).
Cigarette smoke contains thousands of toxic compounds including
cyanide [67] which may cause tissue damage and inﬂammation
and modulate immune cell function and cytokine production
[68,69]. An increased frequency of citrullinated protein in broncho-
alveolar lavage (BAL) cells has been shown in the lungs for healthy
smokers and smokers with pulmonary inﬂammation [70]. The
increase of citrullinated protein was associated with increased
expression of PAD2 in the bronchial mucosal and alveolar compart-
ment, which leads to the possibility of smoking increasingFig. 1. Hypothetical etiological model for the development of ACPA-positive RA illus
oropharynx followed by the effector phase of pathogenesis in the joint.citrullination due to the increased expression of PAD enzyme in
BAL cells. The cyanide present in tobacco smoke could also contrib-
ute to the onset of RA by increasing tissue thiocyanate ions as a re-
sult of its metabolism, or its reaction with protein disulphide
bonds and the subsequent removal of thiocyanate from intermedi-
ate under basic conditions [71]. Thiocyanate can undergo enzy-
matic reactions catalysed by myeloperoxidase that eventually
lead to the formation of homocitrulline. Homocitrulline is homolo-
gous to citrulline in terms of shape and charge, the only difference
being an extra carbon in the side chain. It is frequently found at
sites of inﬂammation and atherosclerotic plaques, both of which
are more common in smokers [72]. Although homocitrullination
is an attractive hypothesis for explaining a direct relationship be-
tween RA and smoking, the remarkable disease speciﬁcity of ACPA
in RA has not yet been replicated using homocitrullinated peptides
as substrates for detecting autoantibodies in human disease.
Importantly, one should also bear in mind that in vitro smoking
studies use different compounds, cells, and experimental condi-
tions to mimic smoking, and may only partly reproduce the true
short- and long-term physiological events accompanying tobacco
smoking.
2.3.2. Porphorymonas gingivalis infection
Besides smoking, P. gingivalis is another environmental agent
that has been linked to RA [73]. Periodontitis, in which P. gingivalis
is a major pathogen, arises as a result of inﬂammatory responses to
the accumulation of bacteria on tooth surfaces adjacent to the
supra- and sub-gingival tissues. Periodontitis and RA share a num-
ber of common predisposing genetic and environmental risk
factors. For example, the DRB1⁄04 SE subtypes (0401, 0404, 0405trating mechanisms of citrullination and tolerance breakdown in the lungs and
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ciated with the development of severe, rapidly progressive peri-
odontitis [74]. Furthermore, in patients with coexistent
rheumatoid arthritis and periodontitis, both articular and peri-
odontal bone erosions are associated with the SE [75]. Periodontitis
and RA also share common inﬂammatory mechanisms.
In addition to the genetic and environmental susceptibility fac-
tors shared by RA and periodontitis, the action of the P. gingivalis
PAD enzyme (PPAD) elevates levels of citrullinated proteins and
may have a role in priming autoimmunity in a subset of patients
with RA [76]. P. gingivalis produces many virulence factors includ-
ing extracellular cysteine proteases (called gingipains), haemag-
glutins, Lipopolysaccharide (LPS), and ﬁmbrae, which enable the
bacterium to colonize and invade periodontal pockets [77]. The
proteolytic processing of P. gingivalis gingipains generates car-
boxy-terminal arginine residues that facilitates the generation of
endogenous c-terminal citrullinated peptides by PPAD [78]. P. gin-
givalis is also capable of citrullinating host human peptides at the
site of gingival inﬂammation [78]. Wegner et al. (2010) demon-
strated in this study that PPAD citrullinates human ﬁbrinogen
and a-enolase peptides after proteolytic cleavage by P. gingivalis
gingipains. P. gingivalis gingipains can also cleave and activate
the human proteinase-activated receptor-2 (PAR-2) on human
neutrophils, which increases intracellular calcium concentrations
[79]. The human PAD enzymes, which require a calcium rich envi-
ronment for activation, could subsequently citrullinate peptidyl
arginines.
We have recently tested the hypothesis that citrullination of
peptides from endogenous proteins generated by P. gingivalis could
be one source of antigen that prime ACPA production in individuals
who subsequently develop RA. Preliminary data suggest that these
peptides generated by P. gingivalis are not as immunoreactive with
autoantibodies as their equivalent internally citrullinated counter-
peptides (Quirke AM et al., unpublished observations). However, it
remains possible that these peptides could breach tolerance to cit-
rullinated proteins long before the development of RA.
2.4. Mechanisms of tolerance breakdown
What distinguishes RA from other inﬂammatory joint diseases
is not the presence of synovial citrullination but the immune re-
sponse to citullinated proteins. The conditions required to trigger
this immune response in a physiological context are not well
known. It is often assumed that a T cell response to citrullinated
peptides is necessary. This would require the uptake and process-
ing of citrullinated antigens by antigen presenting cells (APCs) with
subsequent presentation by HLA-DR molecules containing the SE
binding motif. The interaction of the peptide/SE complex with spe-
ciﬁc CD4+ T cells in the context of co-stimulation would lead to the
perpetuation of inﬂammation.
Hill et al. [80] tested the hypothesis that citrullination might
evoke an autoimmune response by studying the T cell response
to citrulline-containing peptides in HLA-DRB1⁄0401 transgenic
(DR4-IE tg) mice. They found that citrullination of a vimentin-
related peptide, one of the potential target autoantigens found in
the joint, dramatically increased peptide-0401 binding (100-fold)
and led to the activation of CD4+ T cells. The target arginine/citrul-
line of vimentin was positioned at the P4 peptide-anchoring pock-
et. Feitsma et al. [81] identiﬁed two naturally processed peptides
from citrullinated vimentin that induced a citrulline speciﬁc T cell
response following immunisation, and which also stimulated T
cells from RA patients. These T cells might in turn provide B cell
help and stimulate the production of ACPA. Another study using
the same DR4-IE tg mice found that citrullinated peptide se-
quences of the a- and b-chains of a second target autoantigen,
ﬁbrinogen, had a higher binding afﬁnity to DR4 compared to theuncitrullinated peptides. The signiﬁcance of this was demonstrated
in vivo in an animal model where immunisation of the DR4-IE tg
mice with ﬁbrinogen citrullinated in vitro induced a progressive
arthritis, which was not seen in the wild type mice or with the
transgenic mice immunised with native ﬁbrinogen [82]. Citrul-
line-speciﬁc-DR4 restricted T cell responses against the naturally
processed vimentin peptides present in the inﬂamed joint were
also demonstrated in the study. These studies suggest that citrulli-
nated peptides, capable of binding to HLA-DR SE can elicit an auto-
immune response which is then maintained by reactivity with
citrullinated proteins within the joint.
Veriﬁcation of the pathogenicity of citrulline speciﬁc T cells in
mice is complicated by several factors. Firstly, citrullinated pro-
teins do not accumulate in the normal healthy joint. Secondly,
murine MHC and autoantigens vary between mouse and man,
which means that different T cell clones exist in a naïve mouse
and a healthy patient prior to a breach in immunological tolerance.
Therefore, the absence of arthritis in the DR4-IE mice immunised
with citrullinated vimentin is likely to be, at least in part, due to
the absence of citrullinated vimentin in healthy mouse joints.
However, in the study by Hill et al. [82], the authors overcame both
of these hurdles by transferring T cells from DR4-IE mice (immun-
ised with in vitro citrullinated human ﬁbrinogen) into naïve recip-
ients, who had been given intra-articular human or mouse
ﬁbrinogen. The arthritis could only be transferred when the recipi-
ent mouse received intra-articular citrullinated ﬁbrinogen. This
supports the previously suggested hypothesis [11] that in order
for either citrulline speciﬁc T or B cells to become pathogenic,
either the synovium must itself become inﬂamed, or citrullinated
proteins produced elsewhere must be deposited there.
P. gingivalis may play a role in tolerance breakdown by promot-
ing ACPA production to self citrullinated peptides and host citrul-
linated peptides. Lundberg et al. [76] showed that RA patients
with a humoral immune response to CEP-1 had antibodies also
reactive with a CEP-1 enolase orthologue from P. gingivalis. This
suggested that P. gingivalis infection could break tolerance by cit-
rullinating bacterial enolase, with the subsequent antibody re-
sponse cross-reacting with citrullinated human a-enolase and
initiating ACPA production [76]. Hitchon et al. [83] revealed an
association between the IgG immune response to P. gingivalis lipo-
polysaccharide and ACPA in a genetically predisposed population
of North American Native individuals with RA. Our research group
(Kinloch et al. [84]) recently tested the arthritogenicity of citrulli-
nated enolase from both humans and P. gingivalis using the same
DR4-IE transgenic mouse model used by Hill et al. [82] and control
mice (MHC class II knockout and C57BL/6). Both the human and P.
gingivalis citrullinated enolase induced arthritis in the DR4-IE mice.
However, antibodies reacting with citrullinated and uncitrullinat-
ed enolase, as well as antibodies to CEP-1 and the arginine control
peptide, were found in all groups apart from the MHC class II
knockout mice. This suggests that enolase is different in that it is
the uncitrullinated molecule that may break tolerance in the con-
text of the DR4 risk alleles and provides a novel model for investi-
gating an etiological role for P. gingivalis in RA.
Smoking may breach tolerance through the generation of
homocitrullinated proteins. Recent evidence in support of this
hypothesis has shown that immunisation of mice with homocitrul-
line-containing peptides induced anti-homocitrulline antibodies as
well as the proliferation and chemotaxis of CD4+ T cells and the
production of proinﬂammatory cytokines [85]. The authors also
found increased levels of both homocitrullinated peptides and
citrullinated-peptides in patients with erosive arthritis and
importantly the level of homocitrullinated peptides was found to
be greatest in patients with erosive arthritis that were also anti-
CCP positive. It has also been shown that some positive results
with anti-CCP2 assays possibly reﬂect cross-reactivity with
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homocitrullinated proteins both developed anti-CCP antibodies
[86].3. Effector mechanisms
We have indicated how known genetic and environmental fac-
tors could drive citrulline autoimmunity. However, smoking and/
or P. gingivalis infection are not sufﬁcient for the mature autoim-
mune response. Production of antibodies to citrullinated peptides
occur before onset of disease and are a major feature in substan-
tially increasing the risk of developing RA. This has been supported
bymouse data where administration of ACPA (raised against citrul-
linated ﬁbrinogen antibodies) alone did not cause arthritis. How-
ever, mice subjected to mild CIA developed a more severe
arthritis after administration of ACPA [87]. Clinical studies have
demonstrated how patients with an undifferentiated arthritis that
are ACPA positive are much more likely to progress to RA (as de-
ﬁned in the 1987 ACR criteria) than ACPA negative patients
[88,89]. An important step following tolerance breakdown to
speciﬁc citrullinated peptides generated outside the joint may be
epitope-spreading to other host citrullinated proteins in the
inﬂamed joint, ultimately giving rise to immune complexes with
ACPA and RF. Epitope spreading describes an increase or shift in
antigen recognition during the course of an immune response
[90]. It has been observed in the DR4 RA mouse model induced
by immunisation with citrullinated ﬁbrinogen [80,91], and in a
study of pre-RA sera [92] .3.1. Immune complex formation in the inﬂamed joint
Recent work has elucidated many of the mechanisms by which
ACPA could lead to downstream TNF production and synovial
inﬂammation. Immune complexes formed from solid-phase citrul-
linated ﬁbrinogen and ACPA from human sera, were able to stimu-
late TNF production from macrophages [93]. Fibrinogen was
immobilised in this model to replicate the synovial ﬁbrin deposits
observable in RA. However, circulating immune complexes con-
taining citrullinated ﬁbrinogen can also be identiﬁed in more than
half of patients with anti-CCP antibodies [94]. Whether these are
capable of stimulating macrophages/monocytes in the same way
is unclear, since Mathsson reported that only immune complexes
derived from synovial ﬂuid and not from blood were able to elicit
TNF from peripheral blood mononuclear cells [95]. They did not
identify the complexed antigens however. The effect on TNF pro-
duction in these systems appears dependent on Fcc receptor IIa
(FccRIIa) binding, which is consistent with the increased suscepti-
bility to collagen-induced arthritis in mice transgenic for human
FccRIIa [96]. It seems likely that other citrullinated antigens be-
sides ﬁbrinogen are involved and, using a proteonomic approach,
van Steendam also identiﬁed citrullinated vimentin in synovial
ﬂuid immune complexes [97].
Macrophages may also be activated by Toll-like receptor (TLR)
binding. TLRs comprise part of the innate immune system and
are capable of recognising conserved microbial sequences as well
as endogenous ligands such as RNA and DNA. Fibrinogen has pre-
viously been demonstrated to bind to TLR4 [98,99], but citullina-
tion of ﬁbrinogen enhances its ability to stimulate TNF
production from macrophages. Co-ligation of both FccR and TLR4
by immune complexes containing citrullinated ﬁbrinogen further
increases TNF [100]. Interestingly, RA synovial macrophages ap-
pear more susceptible to activation by TLR 2 and 4 binding, than
macrophages from patients with other arthritides or healthy con-
trols [101], and there is preliminary evidence that blockade of
TLR4 may improve the signs and symptoms of RA [102].ACPA may also stimulate macrophages independent of Fcc and
TLR4 binding. Lu and colleagues identiﬁed the chaperone glucose-
regulatory protein 78 (Grp78, also known as binding immunoglob-
ulin protein; BiP) as being present in a citrullinated form on the
surface of monocytes. This was a target for antibodies present in
afﬁnity-puriﬁed ACPA from pooled RA sera which, when bound, in-
duced TNF expression [103].
3.2. TNFa production leading to joint destruction and inﬂammation
ACPA mediated immune complexes are capable of causing
imbalances in the regulation of cytokines and other inﬂammatory
mediators leading to the inﬂammatory bone erosion characteristic
of RA. This osteo-destructive feature of chronic inﬂammatory
arthritis is a major cause of disability in patients with RA. Besides
TNF-a, several other cytokines play a role in RA pathophysiology,
such as interleukin-1 (IL-1), IL-6, IL-15, IL-17, IL-18, IL-32 and IL-
33, leading to activation and recruitment of inﬂammatory cells (re-
viewed in [104]). However the importance of TNF-a in the mecha-
nism of rheumatoid inﬂammation was indicated in a study by
Brennan et al. [105] where addition of TNF-a-speciﬁc antibodies
at the beginning of cell culture abrogated IL-1 production (which
has been shown to be involved in joint damage in experimental sit-
uations). Consistent with this dominant role of TNF-a in vitro, Kol-
lias and colleagues (1991) demonstrated in vivo that the
overexpression of TNF-a in transgenic mice was sufﬁcient to cause
arthritis [106]. The widespread regulatory effect of anti-TNF
antibodies, including the downregulation of expression of other
pro-inﬂammatory cytokines, such as granulocyte-macrophage
colony-stimulating factor (GM-CSF), IL-6, and IL-8 have been
shown in subsequent experiments [107–109].
As well as increasing expression of other pro-inﬂammatory
cytokines and perpetuating the inﬂammatory process, TNF-a pro-
duction (in association with the other proinﬂammatory cytokines)
activates synovial ﬁbroblasts and macrophages to produce carti-
lage-destructive enzymes, such as metalloproteinases (MMPs)
and expression of bone-destruction related molecules, such as
RANKL (receptor activator of NFj B ligand) causing the cartilage
and bone erosion characteristic of RA [104]. The role of two MMPs,
MMP1 and MMP3, are of particular signiﬁcance in RA as they can
degrade all the important structural proteins in the extracellular
matrix of cartilage [110], and are found at elevated levels in the
serum of RA patients, which is thought to originate from the syn-
ovium [111].
TNF-a also plays an important role in other pathways that con-
tribute to bone erosion in RA. One mechanism involves activated T
cells, long known to stimulate osteoclast formation [112]. The
requirement of osteoclasts in joint destruction in RA was demon-
strated in an experiment where transgenic mice that expressed hu-
man TNF-a and that developed a severe and destructive arthritis
were crossed with osteopetroric mice completely lacking osteo-
clasts [113]. Although the mice exhibited severe inﬂammatory
changes, they did not experience any bone destruction, demon-
strating that TNF-dependent bone erosion is mediated by osteo-
clasts. Another driver of bone erosion in RA involves TNF-a in
association with IL-1 and probably IL-6 driving RANKL expression
and release from T-cells, osteoblasts and synovial ﬁbroblasts
[110]. RANKL stimulates the differentiation of monocytes to osteo-
clasts, which can remove mineral as well as matrix and subse-
quently cause bone destruction. RANKL activates the receptor
antagonist of NFj B (RANK) on the surface of osteoclast precursors,
and this interaction is crucial for osteoclast formation [114].
Dougall et al. [115] showed that mice unable to express either
RANKL or RANK are osteopetrotic because of a complete lack of
osteoclasts. TNF also regulates synovial angiogenesis, which may
be critical in maintaining an invasive mass of inﬂammatory
3686 A.-M. Quirke et al. / FEBS Letters 585 (2011) 3681–3688synovial tissue, and anti-TNF agents downregulate both vascularity
and the pro-angiogenic vascular endothelial growth factor (VEGF)
[116].
4. Concluding remarks
The cardinal features of RA, inﬂammation and joint destruction,
can thus be accounted for by the chronic over production of TNF-a.
The dominance of TNF in the hierarchy of the cytokine cascade and
the remarkable therapeutic advances with the introduction of
TNF-a inhibitors has led to a focus on effector mechanisms when
considering the pathogenesis of RA. We have summarised recent
evidence that overproduction of TNF-a can be caused by immune
complexes containing citrullinated antigens and their antibodies.
This implies that cirullination itself is critical to the cause of the
disease and that these events, well upstream of TNF-a in the
pathogenic pathways of RA hold the key to our understanding of
aetiology and ultimately prevention and cure of this disease.
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